Dirui Medical's revenue in 2025 was RMB 8.07 billion, a year-on-year decrease of 17.41%. The company reported a net loss of RMB 2.55 billion after deducting non-recurring items, and its overseas revenue exceeded 50% for the first time.

The company's revenue for 2025 amounted to 807 million yuan, representing a year-on-year decrease of 17.41%. The net profit attributable to shareholders recorded a loss of 246 million yuan, while the non-recurring net profit loss stood at 255 million yuan, reflecting a sharp decline of 546.99% year-on-year. Overseas revenue exceeded domestic revenue for the first time, with reagents accounting for more than half of total revenue. However, this failed to mask the deterioration in profitability. The audit report issued a qualified opinion and an adverse opinion on internal controls. A significant divergence was observed between the positive operating cash flow and the substantial losses.

lanjinger.comApr 30 12:10

Dere Medical: Financial Statements and Related Notes Following Correction of Accounting Errors

SZSIApr 30 00:00 · Announcements

Dere Medical: First Quarter Report for 2026

SZSIApr 30 00:00 · Announcements

Dere Medical: 2025 Annual Report

SZSIApr 30 00:00 · Announcements

Dere Medical: Summary of the 2025 Annual Report

SZSIApr 30 00:00 · Announcements

Express News | Dirui Medical: Due to the issuance of an adverse opinion on the internal control audit report for the fiscal year 2025, the company's stock trading will be subject to other risk warnings.

BreakingsApr 29 20:40